Hanoll Phosphoren Injection 1 gram (Cefazedone Sodium)

Adult administration

As cefazolin sodium, in cases of infection due to gram-positive bacteria, 1-2 g (potency) should be administered by intravenous injection in divided doses 2-3 times a day. In cases of infection due to gram-negative bacteria, 3-4 g (potency) should be administered by divided doses 2-3 times a day. For life-threatening infections and infections caused by moderately susceptible bacteria, the dose may be increased up to 6 g (potency) per day. For intravenous injection, dissolve 1 g (potency) in 5 mL of injection water and inject slowly over 2-3 minutes.

This medication should not be used in patients with hypersensitivity to cephalosporin antibiotics. It is also advisable not to administer it to premature infants and newborns. Pregnant women in the first three months of pregnancy and patients with renal or liver dysfunction should use this drug cautiously. Patients with hemophilia or thrombocytopenia, as well as those with gastrointestinal ulcers, should also take precautions. Patients who have difficulty in oral intake, those receiving parenteral nutrition, elderly patients, and those in poor general condition should be closely monitored as they may exhibit symptoms of vitamin K deficiency. Mild hypersensitivity reactions such as headache, dizziness, and nausea may occur when using this medication, and rare instances of skin rash, fever, and severe allergic reactions may arise, so caution is advised. Liver function test results may show a temporary increase, and transient leukopenia may also occur. Gastrointestinal issues may include severe colitis, abdominal pain, diarrhea, nausea, vomiting, and loss of appetite, and if symptoms arise, consultation with a physician should be sought immediately. Respiratory symptoms such as fever, cough, and difficulty breathing may rarely occur; in such cases, administration should be stopped immediately, and appropriate treatment should be received. Rarely, microbiota disturbances resulting in oral inflammation or candidiasis may occur. Attention should also be paid to bleeding tendencies due to vitamin K deficiency and symptoms of vitamin B complex deficiency. This medication should be used for the appropriate duration based on susceptibility testing to prevent the emergence of resistant bacteria, and a thorough medical history and skin testing are recommended before administration to prevent allergic reactions. Emergency measures should be prepared for acute allergic reactions, and the patient should be observed in a stable condition. Caution is needed when using this medication in conjunction with aminoglycoside antibiotics, polymyxin B, colistin, and high-dose diuretics, as these may affect renal function. Moreover, when used with high-dose oral anticoagulants, blood coagulation status should be closely monitored. If breastfeeding, it should be used cautiously as small amounts may be transferred to breast milk. Finally, this medication should not be mixed in the syringe with aminoglycoside antibiotics for injection.

Serious side effects

• Anaphylaxis
• severe colitis (with bloody stools)
• difficulty breathing
• interstitial pneumonia
• PIE syndrome.

Mild side effects

Transient mild headache, dizziness, nausea, skin rash, fever, increase in AL-P, GOT, GPT, transient leukopenia, nausea, vomiting, loss of appetite, abdominal pain, frequent diarrhea, stomatitis, candidiasis, symptoms of vitamin K deficiency (hypoprothrombinemia, bleeding tendency), symptoms of vitamin B complex deficiency (glossitis, stomatitis, loss of appetite, neuropathy), fever, cough, eosinophilia, etc.

This medication should be stored in a sealed container to prevent exposure to air and moisture and should be kept at a temperature between 1°C and 30°C (room temperature). Storing it this way will help maintain the drug's efficacy over a longer period.

Appearance

A colorless, transparent vial filled with a white to yellowish powder.

Package unit

1g/vial x 10 vials, 1g/vial x 50 vials